Skip to content
2000
Volume 20, Issue 13
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Polypharmacology offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases. It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these. Polypharmacology can involve combinations and/or multitarget drugs (MTD). Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations. This review article focuses on MTDs from a medicinal chemistry perspective. I will explore their use in current clinical practice, their likely application in the future, and the challenges to be overcome to achieve this goal.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867311320130004
2013-04-01
2025-04-21
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867311320130004
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test